Biotech Values

[DewDiligence]

>what are your thoughts regarding eye drops for retinal disease?<

The issues you raised would seem to make safe and effective eye drops a formidable technical challenge. Several companies have talked about them, but they haven’t followed up. Case in point: OXGN, which told investors almost three years ago that a drop formulation of CA4P was imminent.

For Athenagen, being private may allow them to play their cards close to the vest and ambush the competition if the drops actually work. The companies with the most to worry about from this are probably REGN and RNAI.